Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza ...
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive t...
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply...
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.
JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...
UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $23 to...
https://www.youtube.com/watch?v=esKFMCb_hYUhttps://www.youtube.com/watch?v=esKFMCb_hYU
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) eve...
